

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092761 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number: PCT/US02/14570

(22) International Filing Date: 7 May 2002 (07.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/851,673 8 May 2001 (08.05.2001) US

(71) Applicant (*for all designated States except US*): IMMUNEX CORPORATION [US/US]; Law Department, 51 University Street, Seattle, WA 98101 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): DERRY, Jonathan, M.J. [GB/US]; 3998 El Cimo Lane, Bainbridge Island, WA 98110 (US). FANSLOW, William, C., III [US/US]; 404 S.W. 197th Street, Normandy Park, WA 98166 (US). DOUGALL, William, Conrad [US/US]; 7523 33rd Avenue Northwest, Seattle, WA 98117 (US).

(74) Agent: PERKINS, Patricia, Anne; IMMUNEX CORPORATION, 51 University Street, Seattle, WA 98101 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SCREENING ASSAYS FOR AGONISTS OR ANTAGONISTS OF CD40 SIGNALING



(57) Abstract: The present invention provides methods for identifying a molecule that antagonizes or agonizes CD40 activity by screening for molecules that modulate the binding of NEMO and CYLD. Also provided are assays useful in screening for the binding of NEMO and CYLD and databases and methods useful for analyzing the resultant information.

WO 02/092761 A2

Screening Assays for Agonists or Antagonists of CD40 Signaling

Field of the Invention

This invention relates to methods for screening for agonists and/or antagonists of activities associated with TNF receptor family member CD40.

Background of the Invention

CD40 is a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) receptor family, which is defined by the presence of cysteine-rich motifs in the extracellular region (Smith et al., *Science* 248:1019, 1990; Mallett and Barclay, *Immunology Today* 12:220, 1991; Locksley et al., *Cell* 104:487, 2001). This family includes the lymphocyte antigen CD27, CD30 (an antigen found on Hodgkin's lymphoma and Reed-Sternberg cells), two receptors for TNF, a murine protein referred to as 4-1BB, rat OX40 antigen, NGF receptor, and *Fas* antigen. Similar to other members of the TNF/NGF receptor family, CD40 contains a leader sequence, trans-membrane domain an extracellular domain responsible for binding its native cognate, CD40 ligand (CD40L; described in U.S. Patent Nos. 5,961,974, 5,962,406 and 5,981,724; hereinafter, the Armitage patents). CD40 has been found to be expressed on B lymphocytes, monocytes/macrophages, dendritic cells, smooth muscle cells, microglia, epithelial cells and some carcinoma cell lines.

The cytoplasmic domain of CD40 associates intracellularly with several of the TNF receptor-associated factors (TRAFs; Baker and Reddy, *Oncogene* 12:1 (1996)) including TRAFs 2, 3, 5 and 6 (Pullen et al., *Biochemistry* 37:11836, 1998; Cao et al., *Nature* 383:443, 1996; Ishida et al., *Proc. Natl. Acad. Sci. USA* 93:9437, 1996). The TRAFs are cytoplasmic proteins that often mediate signal transduction by members of the TNF receptor superfamily, and they are important in the regulation of, for example, immune and inflammatory responses.

Triggering of CD40, such as by contact with membrane-bound or soluble CD40 ligand (CD40L), results in the stimulation of CD40-mediated cellular responses. These cellular responses can include the activation of transcription factor NF-kappaB, a ubiquitous transcription factor that is extensively utilized in cells of the immune system. NF-kappaB is normally maintained in the cytoplasm by interaction with IkappaB members (reviewed in Karin, *Oncogene* 18: 6867, 1999; Chen and Gosh, *Oncogene*

18:6845, 1999). Release of NF-kappaB, and subsequent translocation of this transcription factor to the nucleus, result from phosphorylation of IkappaB, which leads to its ubiquitination and degradation. Phosphorylation of IkappaB is mediated by the inducible kappaB kinase (IKK) complex consisting of two kinases, IKKalpha, and
5 IKKbeta, and a scaffolding protein referred to as NEMO (NF-kappaB essential modulator; Yamaoka et al., *Cell* 93:1231, 1998), IKK-gamma (Rothwarf et al., *Nature* 395:297, 1998), FIP3 (Fourteen K interacting protein 3; Li et al., *Proc. Natl. Acad. Sci. USA* 96:1042, 1999) or RAP2 (RIP-associated protein 2; WO 99/47672) (hereinafter, NEMO).

10 NEMO exhibits characteristics of a "signaling scaffold protein", and binds not only to kinases involved in NF-kappaB-mediated signaling, but to proteins that play a role in signaling via TNF and/or Fas (Receptor Interacting Protein 2 or RIP2, McCarty et al., *J. Biol. Chem.* 273:16968, 1998; NF-kappaB Inducing Kinase, NIK, Malinin et al., *Nature* 385:640, 1997; and A20, Cooper et al., *J. Biol. Chem.* 271:18068, 1996), to several viral
15 proteins (Adeno 14.7K, Li et al., *supra*; HTLV Tax, Yamaoka et al., *supra*), and to proteins of unknown function (TIP60, Tat interactive protein 60 kDa, Kamine et al., *Virology* 216:357, 1996; CYLD, a putative tumor suppressor gene associated with familial cylindromatosis, Bignell et al., *Nat. Genet.* 25:160, 2000).

Additionally, a peptide that blocks the interaction of NEMO with IKK-alpha/IKK-
20 beta has been shown to be potent anti-inflammatory agent (May et al., *Science* 289:1550, 2000). Moreover, deletion mutations of NEMO have been shown to cause familial incontinentia pigmentosa (IP; Smahi et al., *Nature* 405:466, 2000), whereas milder mutations in the carboxy-terminal region of NEMO have been linked to ectodermal dysplasia with immunodeficiency/hyperIgM (HED-ID; Zonano et al., *Am. J. Hum. Genet.*
25 67:1555, 2000; Jain et al., *Nature Immunology* 2:223, 2001). Because of the role NEMO plays in numerous signaling pathways, there is a need in the art to identify molecules that can affect the interaction of NEMO with certain molecules (either as antagonists or agonists), to allow regulation of specific pathways in an inflammatory response.

Summary of the Invention

30 The present invention provides methods for screening for a molecule that antagonizes or agonizes the activity of NEMO in CD40 signaling. In one aspect of the invention, there is provided a method for identifying compounds that alter CD40

signaling activity comprising: (a) mixing a test compound with a polypeptide selected from the group consisting of (i) a NEMO polypeptide comprising amino acids 287 through 419 SEQ ID NO:2, (ii) a fragment of a NEMO polypeptide according to (i) that is capable of binding a CYLD polypeptide according to SEQ ID NO:4 or fragment or
5 variant thereof, and (iii) variants of the NEMO polypeptides of (i) and (ii); and (b) determining whether the test compound alters the ability of NEMO to bind CYLD. The invention further provides a method for identifying compounds that inhibit binding of NEMO and CYLD comprising: (a) mixing a test compound with a polypeptide selected from the group consisting of (i) a NEMO polypeptide comprising amino acids 287
10 through 419 SEQ ID NO:2, (ii) a fragment of a NEMO polypeptide according to (i) that is capable of binding a CYLD polypeptide according to SEQ ID NO:4, and (iii) variants of the NEMO polypeptides of (i) and (ii), and a binding partner of said NEMO polypeptide selected from the group consisting of (iv) a CYLD polypeptide according to SEQ ID NO:4, (v) a fragment of a CYLD polypeptide according to SEQ ID NO:4 that is capable
15 of binding a NEMO polypeptide of (i), (ii), or (iii), and (vi) variants of the CYLD polypeptides of (iv) and (v); and (b) determining whether the test compound inhibits the binding activity of said NEMO and CYLD polypeptides.

In one aspect, the inventive methods utilize homogeneous assay formats such as fluorescence resonance energy transfer, fluorescence polarization, time-resolved
20 fluorescence resonance energy transfer, scintillation proximity assays, reporter gene assays, fluorescence quenched enzyme substrate, chromogenic enzyme substrate and electrochemiluminescence. In another aspect, the inventive methods utilize heterogeneous assay formats such as enzyme-linked immunosorbant assays (ELISA) or radioimmunoassays. In yet another aspect of the invention are cell-based assays, for
25 example those utilizing reporter genes, as well as functional assays that analyze the effect of an antagonist or agonist on biological function(s).

The invention further provides methods for producing information comprising the identity of a compound that alters one or more biological activities of CD40, the method comprising using assay methods of the invention to identify one or more compounds that
30 alter the binding of NEMO and CYLD. In one preferred embodiment, the compound decreases (or antagonizes) the binding of NEMO and CYLD, and in another distinct embodiment, the compound increases (or agonizes) the binding of NEMO and CYLD.

Preferably the biological activity of CD40 that is decreased or downregulated is selected from the group consisting of deleterious effects of CD40-mediated immune or inflammatory response (including atherosclerosis, arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), thrombosis, graft versus host disease and/or graft rejection. In a distinct embodiment, the biological activity of CD40 that is increased or upregulated is selected from the group consisting of upregulation of a cell-mediated immune response, upregulation of an antibody-mediated immune response, prevention or treatment of infectious disease, and prevention or treatment of neoplastic disease.

Also provided by the invention is the information produced according to the inventive methods, said information comprising the identity of a compound that alters the biological activity of CD40, and preferably embodied in a storage medium selected from the group consisting of the brains of living organisms, paper, magnetic tape, optical tape, floppy disks, compact disks, computer system hard drives, and computer memory units. In a further aspect, the invention provides a database comprising said information, wherein the information is preferably embodied in a computer-readable medium, and a separate embodiment wherein the information is embodied in a human-readable medium.

Additionally provided by the invention is a computer system comprising a database containing records pertaining to a plurality of compounds, wherein the records comprise results of an assay of the invention, and a user interface allowing a user to access information regarding the plurality of compounds. In another aspect of the invention, a computer system is provided for storing and retrieving data on a plurality of compounds, the computer system comprising: (a) input means for entering data for the compounds into a storage medium; (b) a processor for creating an individual record for each compound, the processor assigning specific identifying values for each compound; (c) means for selecting one or more of the records based on results in an assay; and (d) means for transmitting information in the record or records to an output device to produce a report; preferably a report in human-readable form, and wherein the computer system preferably further comprises a video display unit.

The invention also provides a method of using the computer system of the invention to select one or more compounds for testing from a plurality of compounds having records stored in a database, the method comprising: displaying a list of said records or a field for entering information identifying one or more of said records; and selecting one or more of the records from the list or the record or records identified by

entering information in the field. Further, the invention provides a method of operating a computer system for analyzing compounds that modulate the interaction NEMO and CYLD, the method comprising: (a) entering data relating to a plurality of compounds into a storage medium; (b) processing the data to create an individual record for each compound; (c) testing compounds for the ability to modulate binding of NEMO to CYLD; and (d) communicating results from the testing into the storage medium such that results for each compound are associated with the individual record for that compound; wherein in one embodiment the storage medium comprises one or more computer memory units, and in another embodiment the computer system further comprises a video display unit.

In yet another aspect of the invention, a database is provided comprising records generated according to the methods of the invention, and a method is provided for selecting compounds that modulate the interaction of NEMO and CYLD, comprising compiling said database, analyzing the testing results, and selecting one or more compounds.

Candidate molecules that are determined to agonize or antagonize a CD40 signaling activity of NEMO are useful, for example, for the further definition of CD40-mediated signaling pathways, and for the manipulation of CD40-mediated cellular responses. Moreover, CD40 signaling agonists and antagonists provide therapeutic agents for treating disorders of the immune system, and inflammatory disorders, as well as treatment of conditions characterized by malignant cells expressing CD40.

Brief Description of the Drawings

Figure 1 depicts the structure NEMO, with various regions highlighted; the amino acid sequence is shown in SEQ ID NO:2. The region from amino acid 217 through 419 is believed to bind CYLD; homodimerization is thought to be mediated by amino acids 217 through 264. Binding to NIK and TIP60 is believed to occur between amino acids 95 and 264, while binding to RIP and A20 is through amino acids 95 through 218. NEMO binds to 14.7K via amino acids 180 through 419; binding to IKK-1 and IKK-2 is mediated by amino acids 44 through 86. The majority of mutations that result in familial IP are deletions of exons 3 through 10. The stippled regions labeled 'αH' are alpha-helical regions 'LZ' represents the leucine zipper region, and 'ZF' denotes the zinc finger. Amino acids 397, 400, 413 and 417 are believed to coordinate zinc.

Detailed Description of the Preferred Embodiment

The present invention provides methods for screening for a molecule that antagonizes or agonizes CD40 signaling activity, utilizing molecules that play a role in signaling through CD40. Two patients with a form of X-linked hyper IgM syndrome with ectodermal dysplasia and normal CD40 and CD40L expression were found to have mutations in NEMO. In one, a T to C mutation at nucleotide 1249 results in a Cys to Arg substitution at amino acid 417 of NEMO (C417R), and in the other, an A to T substitution at nucleotide 1217 results in an Asp to Val mutation at amino acid 406 (V406D). B cells from these patients did not undergo immunoglobulin class switching when contacted with a soluble, oligomeric form of CD40L (described in the Armitage patents, *supra*), and also failed to upregulate CD54 expression. Moreover, antigen-presenting cells from these patient did not synthesize Interleukin-12 (IL-12) and TNF-alpha when stimulated with CD40L and interferon-gamma (IFN-gamma), but did synthesize these two cytokines when stimulated with *S. aureus* Cowan protein A plus IFN-gamma or lipopolysaccharide plus IFN-gamma. Additionally, degradation of IkappaB-alpha in response to TNF or LPS appeared normal in monocytes from these patients, but stimulation with CD40L failed to induce this response.

These findings demonstrated that the zinc finger region of NEMO represents an area of NEMO that is critical for CD40 signal transduction, but that does not appear critical for transduction of signal via other pathways leading to NF-kappaB activation (for example, binding of LPS through the Toll-like receptors, and/or binding of TNF to TNF receptor). Accordingly, peptides derived from this region are likely to be useful in screening for small molecules that inhibit the interaction of this domain of NEMO with other molecules in the CD40 signaling cascade (i.e., CYLD), which will be useful in downregulating or controlling deleterious effects of CD40-mediated immune or inflammatory response. Conditions that are thought to be mediated by CD40 signaling include atherosclerosis, arthritis, multiple sclerosis (MS), systemic lupus erythematosus (SLE), thrombosis, graft versus host disease and/or graft rejection.

Candidate Molecules to be Tested for CD40 Signaling Activity:

The methods of the invention may be used to identify antagonists and agonists of CD40 signaling activity from cells, cell-free preparations, chemical libraries, cDNA libraries, recombinant antibody libraries (or libraries comprising subunits of antibodies)

and natural product mixtures. The antagonists and agonists may be natural or modified substrates, ligands, enzymes, receptors, etc. of the polypeptides of the instant invention, or may be structural or functional mimetics of one of the polypeptides (NEMO or CYLD). Potential antagonists of the instant invention may include small molecules,
5 peptides and antibodies that bind to and occupy a binding site of the inventive polypeptides or a binding partner thereof, causing them to be unavailable to bind to their natural binding partners and therefore preventing normal biological activity. Potential agonists include small molecules, peptides and antibodies which bind to the instant polypeptides or binding partners thereof, and elicit the same or enhanced biologic effects
10 as those caused by the binding of the polypeptides of the instant invention.

Small molecule agonists and antagonists are usually less than 10K molecular weight and may possess a number of physicochemical and pharmacological properties which enhance cell penetration, resist degradation and prolong their physiological half-lives (Gibbs, J., Pharmaceutical Research in Molecular Oncology, Cell, Vol. 79 (1994)).
15 Antibodies, which include intact molecules as well as fragments such as Fab and F(ab')₂ fragments, as well as recombinant molecules derived therefrom (including antibodies expressed on phage, intrabodies, single chain antibodies such as scFv and other molecules derived from immunoglobulins that are known in the art), may be used to bind to and inhibit the polypeptides of the instant invention by blocking the propagation of a
20 signaling cascade. It is preferable that the antibodies are humanized, and more preferable that the antibodies are human. The antibodies of the present invention may be prepared by any of a variety of well-known methods.

Additional examples of candidate molecules, also referred to herein as "test molecules," to be tested for CD40 signaling agonist or antagonist activity include, but are
25 not limited to, carbohydrates, small molecules (usually organic molecules or peptides), proteins, and nucleic acid molecules (including oligonucleotide fragments typically consisting of from 8 to 30 nucleic acid residues). Peptides to be tested typically consist of from 5 to 25 amino acid residues. Also, candidate nucleic acid molecules can be antisense nucleic acid sequences, and/or can possess ribozyme activity.

30 Small molecules to be screened using the hereindescribed screening assays can typically be administered orally or by injection to a patient in need thereof. Small molecules that can be administered orally are especially preferred. The small molecules of the invention preferably will not be toxic at the doses required for them to be effective

as pharmaceutical agents, and they are preferably not subject to rapid loss of activity in the body, such as the loss of activity that might result from rapid enzymatic or chemical degradation. In addition, pharmaceutically useful small molecules are preferably not immunogenic.

5 The methods of the invention can be used to screen for antisense molecules that inhibit the functional expression of one or more mRNA molecules that encode one or more proteins that mediate a CD40-dependent cellular response. An anti-sense nucleic acid molecule is a DNA sequence that is inverted relative to its normal orientation for transcription and so expresses an RNA transcript that is complementary to a target mRNA
10 molecule expressed within the host cell (*i.e.*, the RNA transcript of the anti-sense nucleic acid molecule can hybridize to the target mRNA molecule through Watson-Crick base pairing). An anti-sense nucleic acid molecule may be constructed in a number of different ways provided that it is capable of interfering with the expression of a target protein. Typical anti-sense oligonucleotides to be screened preferably are 30-40
15 nucleotides in length. The anti-sense nucleic acid molecule generally will be substantially identical (although in antisense orientation) to the target gene. The minimal identity will typically be greater than about 65%, but a higher identity might exert a more effective repression of expression of the endogenous sequences. Substantially greater identity of more than about 80% is preferred, though about 95% to absolute identity
20 would be most preferred.

Candidate nucleic acid molecules can possess ribozyme activity. Thus, the methods of the invention can be used to screen for ribozyme molecules that inhibit the functional expression of one or more mRNA molecules that encode one or more proteins that mediate a CD40 dependent cellular response. Ribozymes are catalytic RNA
25 molecules that can cleave nucleic acid molecules having a sequence that is completely or partially homologous to the sequence of the ribozyme. It is possible to design ribozyme transgenes that encode RNA ribozymes that specifically pair with a target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself
30 altered, and is thus capable of recycling and cleaving other molecules. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the antisense constructs.

The design and use of target RNA-specific ribozymes is described in Haseloff et al. (*Nature*, 334:585, 1988; see also U.S. Patent No.5,646,023), both of which publications are incorporated herein by reference. Tabler et al. (*Gene* 108:175, 1991) have greatly simplified the construction of catalytic RNAs by combining the advantages of the anti-sense RNA and the ribozyme technologies in a single construct. Smaller regions of homology are required for ribozyme catalysis, therefore this can promote the repression of different members of a large gene family if the cleavage sites are conserved.

NEMO and CYLD Molecules

Generally, the screening assays described herein involve a NEMO and a CYLD protein, or nucleic acid encoding such. NEMO and the NEMO-binding molecule CYLD and nucleic acids encoding these proteins are known in the art. The nucleotide sequence of a DNA encoding NEMO, and amino acid sequence encoded by this DNA, are set forth in SEQ ID NOs:1 and 2, respectively. The nucleotide sequence of a DNA encoding CYLD, and amino acid sequence encoded by this DNA, are set forth in SEQ ID NOs:3 and 4, respectively. However, it is understood that other NEMO and CYLD variants other than those shown in these examples may be used in the hereindisclosed assays, including other NEMO and CYLD molecules known in the art, or variants having similar properties.

Sequence variants of native NEMO and CYLD polypeptides are useful in the practice of the present invention in any instance where the native NEMO or CYLD polypeptide is utilized, provided that the variant possesses any biological activity required for the assay. Generally for these assays, suitable NEMO variants will bind CYLD. Mutations present in such variants may include, for example, substitutions, deletions, and insertions of amino acids. Allelic forms or mutated forms of NEMO and CYLD can be obtained for use in these assays by using a variety of techniques known in the art, including, for example, site-directed mutagenesis, oligonucleotide-directed mutagenesis, and so on.

Also useful in the inventive methods are fragments of NEMO and/or CYLD. Particularly useful fragments of NEMO include the region from about amino acid 300 to 419, comprising a leucine zipper and zinc finger domain, and the region from about amino acid 387 to 419, comprising the zinc finger domain (see Figure 1); additional fragments thereof that bind CYLD can be identified as described herein, and will also be

useful in the present methods. Such fragments include those that are truncated by about five to ten amino acids (i.e., fragments from x to y, wherein x is selected from the group consisting of 386, 385, 384, 3843, 382, 381, 380 379, 378 and 377, and y is selected from the group consisting of 409, 410, 411, 412, 413, 414, 415, 416, 417, 418 and 419, and in particular, 418 and 419), and those having an N-terminus between amino acid 300 and 387 (i.e., fragments from x to y, wherein x is an integer between 300 and 387, and y is selected from the group consisting of 409, 410, 411, 412, 413, 414, 415, 416, 417, 418 and 419). Particularly useful fragments of CYLD include those that are capable of binding NEMO.

Sequence variants of NEMO and CYLD polypeptides that are not capable of binding their native binding partner may also useful in any of the assays described herein. In one embodiment, such sequence variants are useful as controls for an assay. In another embodiment, sequence variants that do not bind their respective binding partners will be useful in screening for molecules that facilitate the binding of NEMO and CYLD despite the inability of the sequence variants to bind in the absence of the facilitating molecule. Such facilitating molecules will be useful in treating disease conditions characterized by an inability of NEMO to bind to CYLD (i.e., X-linked hyper IgM with ectodermal dysplasia). Useful sequence variants can be obtained as described herein.

NEMO and/or CYLD peptides that are useful in the inventive methods (including fragments such as those mentioned previously) may be expressed as fusion proteins with tag peptides that facilitate detection and/or purification. Such peptides include, for example, poly-His or the antigenic identification peptides described in U.S. Patent No. 5,011,912 and in Hopp et al., *Bio/Technology* 6:1204, 1988. Additional, useful tag proteins include green fluorescent protein (GFP; Chalfie et al., *Science* 263:802, 1994), an N-terminal peptide that contains recognition sites for a monoclonal antibody, a specific endopeptidase, and a site-specific protein kinase (PKA; Blonar and Rutter, *Science* 256:1014, 1992), birA (Altman et al., *Science* 274:94, 1996).and glutathione S transferase (GST: Smith and Johnson, *Gene* 67:31, 1988).

One such tag peptide is the FLAGTM peptide, which is highly antigenic and provides an epitope reversibly bound by a specific monoclonal antibody, enabling rapid assay and facile purification of expressed recombinant protein. A murine hybridoma designated 4E11 produces a monoclonal antibody that binds the FLAGTM peptide in the presence of certain divalent metal cations, as described in U.S. Patent 5,011,912, hereby

incorporated by reference. The 4E11 hybridoma cell line has been deposited with the American Type Culture Collection under accession no. HB 9259. Monoclonal antibodies that bind the FLAGTM peptide are available from Eastman Kodak Co., Scientific Imaging Systems Division, New Haven, Connecticut.

5 Another useful tag peptide is the GST peptide, which binds glutathione, also facilitating purification of expressed recombinant protein. Recombinant protein can be purified by affinity chromatography using a suitable chromatography matrix to which has been attached glutathione, as described in Smith and Johnson, supra, hereby incorporated by reference. Suitable chromatography matrixes include Glutathione-Agarose beads
10 (Pharmacia, Uppsala, Sweden). Recombinant protein can be eluted with an excess of glutathione. Fragments of NEMO comprising the zinc finger domain (as described above) and a GST peptide are preferred.

The proteins useful in the practice of the present invention typically have an amino acid sequence that is at least 80% identical, or at least 85% identical, or preferably
15 at least 90% identical to all or a portion of the corresponding native protein as set forth in SEQ ID NOS:2 or 4. Percent identity is defined as the percentage of the amino acid residues set forth in SEQ ID NOS:2, or 4, that are identical with part or all of another protein sequence (which may be a portion of a larger protein sequence) after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity.
20 For comparing amino acid sequences of unequal length, the percent identity is calculated based on the smaller of the two sequences.

Preferably, the comparison is done using a computer program. An exemplary, preferred computer program is the Genetics Computer Group (GCG; Madison, WI) Wisconsin package version 10.0 program, 'GAP.' The preferred default parameters for
25 the 'GAP' program includes: (1) The GCG implementation of the previously stated comparison matrixes for nucleotides and amino acids; (2) a penalty of 30 for each gap and an additional penalty of 1 for each symbol in each gap for amino acid sequences, or penalty of 50 for each gap and an additional penalty of 3 for each symbol in each gap for nucleotide sequences; (3) no penalty for end gaps; and (4) no maximum penalty for long
30 gaps. Another program useful for determining percent identify is the BESTFIT program, also available from the University of Wisconsin as part of the GCG computer package. Default parameters for using the BESTFIT program are the same as those described above for using the GAP program.

Screening Assays for NEMO and CYLD:

Specific screening methods are known in the art and along with integrated robotic systems and collections of chemical compounds/natural products are extensively incorporated in high throughput screening so that large numbers of test compounds can be tested for antagonist or agonist activity within a short amount of time. These methods include homogeneous assay formats such as fluorescence resonance energy transfer, fluorescence polarization, time-resolved fluorescence resonance energy transfer, scintillation proximity assays, reporter gene assays, fluorescence quenched enzyme substrate, chromogenic enzyme substrate and electrochemiluminescence, as well as more traditional heterogeneous assay formats such as enzyme-linked immunosorbant assays (ELISA) or radioimmunoassays. Homogeneous assays are preferred. Also comprehended herein are cell-based assays, for example those utilizing reporter genes, as well as functional assays that analyze the effect of an antagonist or agonist on biological function(s) (for example, secretion of cytokines or immunoglobulin class switching).

Moreover, combinations of screening assays can be used to find molecules that regulate the biological activity of NEMO and/or CYLD. Molecules that regulate the biological activity of a polypeptide may be useful as agonists or antagonists of the peptide. In using combinations of various assays, it is usually first determined whether a candidate molecule binds to a polypeptide by using an assay that is amenable to high throughput screening. Binding candidate molecules identified in this manner are then added to a biological assay to determine biological effects. Molecules that bind and that have an agonistic or antagonistic effect on biologic activity will be useful in treating or preventing disease or conditions with which the polypeptide(s) are implicated.

Generally, an antagonist will inhibit the activity by at least 30%; more preferably, antagonists will inhibit activity by at least 50%, most preferably by at least 90%. Similarly, an agonist will enhance the activity by at least 20%; more preferably, agonists will enhance activity by at least 30%, most preferably by at least 50%. Those of skill in the art will recognize that agonists and/or antagonists with different levels of agonism or antagonism respectively may be useful for different applications (i.e., for treatment of different disease states).

Homogeneous assays are mix-and-read style assays that are very amenable to robotic application, whereas heterogeneous assays require separation of free from bound

analyte by more complex unit operations such as filtration, centrifugation or washing. These assays are utilized to detect a wide variety of specific biomolecular interactions (including protein-protein, receptor-ligand, enzyme-substrate, and so on), and the inhibition thereof by small organic molecules. These assay methods and techniques are well known in the art (see, e.g., High Throughput Screening: The Discovery of Bioactive Substances, John P. Devlin (ed.), Marcel Dekker, New York, 1997 ISBN: 0-8247-0067-8). The screening assays of the present invention are amenable to high throughput screening of chemical libraries and are suitable for the identification of small molecule drug candidates, antibodies, peptides, and other antagonists and/or agonists, natural or synthetic.

One such assay is based on fluorescence resonance energy transfer (FRET; for example, HTRF®, Packard BioScience Company, Meriden, CT; LANCE™, PerkinElmer LifeSciences, Wallac Oy., Turku, Finland) between two fluorescent labels, an energy donating long-lived chelate label and a short-lived organic acceptor. The energy transfer occurs when the two labels are brought in close proximity via the molecular interaction between NEMO and CLD. In a FRET assay for detecting inhibition of the binding of NEMO and CYLD, europium chelate or cryptate labeled NEMO or CYLD serves as an energy donor and streptavidin-labeled allophycocyanin (APC) bound to the appropriate binding partner (i.e., CYLD if NEMO is labeled, or NEMO if CYLD is labeled) serves as an energy acceptor. Once NEMO binds CYLD, the donor and acceptor molecules are brought in close proximity, and energy transfer occurs, generating a fluorescent signal at 665 nm. Antagonists of the interaction of NEMO and CYLD will thus inhibit the fluorescent signal, whereas agonists of this interaction would enhance it.

Another useful assay is a bioluminescence resonance energy transfer, or BRET, assay, substantially as described in Xu et al., *Proc. Natl. Acad. Sci. USA* 96:151 (1999). Similar to a FRET assay, BRET is based on energy transfer from a bioluminescent donor to a fluorescent acceptor protein. However, a green fluorescent protein (GFP) is used as the acceptor molecule, eliminating the need for an excitation light source. Exemplary BRET assays include BRET and BRET² from Packard BioScience, Meriden, CT.

DELFI® (dissociated enhanced lanthanide fluoroimmunoassay; PerkinElmer LifeSciences, Wallac Oy., Turku, Finland) is a solid-phase assay based on time-resolved fluorometry analysis of lanthanide chelates (see, for example, US Patent 4,565,790, issued January 21, 1986). For this type of assay, microwell plates are coated with a first

protein (NEMO or CYLD). The binding partner (CYLD or NEMO, respectively) is conjugated to europium chelate or cryptate, and added to the plates. After suitable incubation, the plates are washed and a solution that dissociates europium ions from solid phase bound protein, into solution, to form highly fluorescent chelates with ligands present in the solution, after which the plates are read using a reader such as a VICTOR²™ (PerkinElmer LifeSciences, Wallac Oy., Turku, Finland) plate reader to detect emission at 615 nm).

Another assay that will be useful in the inventive methods is a FlashPlate® (Packard Instrument Company, IL)-based assay. This assay measures the ability of compounds to inhibit protein-protein interactions. FlashPlates® are coated with a first protein (either NEMO or CYLD), then washed to remove excess protein. For the assay, compounds to be tested are incubated with the second protein (CYLD, if the plates are coated with NEMO, or NEMO if plates are coated with CYLD) and I¹²⁵ labeled antibody against the second protein and added to the plates. After suitable incubation and washing, the amount of radioactivity bound is measured using a scintillation counter (such as a MicroBeta® counter; PerkinElmer LifeSciences, Wallac Oy., Turku, Finland).

The AlphaScreen™ assay (Packard Instrument Company, Meriden, CT). AlphaScreen™ technology is an "Amplified Luminescent Proximity Homogeneous Assay" method utilizing latex microbeads (250 nm diameter) containing a photosensitizer (donor beads), or chemiluminescent groups and fluorescent acceptor molecules (acceptor beads). Upon illumination with laser light at 680 nm, the photosensitizer in the donor bead converts ambient oxygen to singlet-state oxygen. The excited singlet-state oxygen molecules diffuse approximately 250 nm (one bead diameter) before rapidly decaying. If the acceptor bead is in close proximity to the donor bead (i.e., by virtue of the interaction of NEMO and CYLD), the singlet-state oxygen molecules reacts with chemiluminescent groups in the acceptor beads, which immediately transfer energy to fluorescent acceptors in the same bead. These fluorescent acceptors shift the emission wavelength to 520-620 nm, resulting in a detectable signal. Antagonists of the interaction of NEMO and CYLD will thus inhibit the shift in emission wavelength, whereas agonists of this interaction would enhance it.

One embodiment of a method for identifying molecules which inhibit or antagonize CD40-mediated signaling involves adding a candidate molecule to a medium which contains cells that express NEMO and CYLD; changing the conditions of said

medium so that, but for the presence of the candidate molecule, NEMO would be bound to CYLD, and observing the binding and stimulation or inhibition of a functional response. The activity of the cells that were contacted with the candidate molecule may then be compared with the identical cells that were not contacted and antagonists and agonists of the polypeptides of the instant invention may be identified. The measurement of biological activity may be performed by a number of well-known methods such as measuring the amount of protein present (e.g. an ELISA) or of the protein's activity. A decrease in biological stimulation or activation would indicate an antagonist. An increase would indicate an agonist.

Computer Analysis of Assay Results

In one aspect of the invention, the assays of the invention are used to identify compounds that alter CD40 signaling activity. The benefits of integrated robotic systems used to analyze collections of chemical compounds/natural products in such assays, which preferably incorporate high-throughput screening methods, are most often realized by the use of sophisticated computer and statistical techniques to manage the resulting data. In one form, the information generated in the inventive screening assays is stored (or compiled) in electronic form, using a computerized database that allows information to be efficiently catalogued and retrieved. Such databases are comprised of records, usually one record for each compound, that includes information about the compound, such as chemical name, structure, source, activity in a binding assay, activity in a biological assay, etc.

The information may be entered into the database manually, that is by a user entering data through a user interface (i.e., keyboard, touchpad, etc.), or it may be entered electronically as in when a robotic system for analysis of compounds generates electronic results that are transferred to another computer system (often referred to as uploading). Such information is usually stored in a discrete area of the record referred to as a field. Additionally, the information, preferably in the form of a database, may be stored permanently or temporarily on various forms of storage media, including paper, the brains of living organisms, compact disks, floppy disks, magnetic tapes, optical tapes, hard drives, computer system memory units, and the like.

The database may be stand-alone, or the records therein may be related to other databases (a relational database). Examples of other databases include publicly available,

well-known databases such as GenBank for peptides and nucleic acids (and associated databases maintained by the National Center for Biotechnology Information or NCBI), and the databases available through www.chemfinder.com or The Dialog Corporation (Cary, North Carolina) for chemical compounds.

5 A user will be able to search the database according to the information recorded (selecting records that have a particular value in a selected field, for example, searching for all compounds that inhibited a binding assay by at least about 30%); accordingly, another aspect of the invention is a method of using a computer system to catalog and store information about various chemical compounds. The ability to store and retrieve
10 such information in computerized form allows those of ordinary skill in the art to select compounds for additional testing, including additional analysis of binding ability, biological testing, and testing in animal models or clinical trials of pharmaceutical agents in humans. Moreover, in addition to storing and cataloging information, the database can be used to provide a report, either in electronic form or in the form of a printout, that will
15 facilitate further analysis of selected compounds.

One embodiment of the invention comprises a computing environment; an input device, connected to the computing environment, to receive information from the user; an output device, connected to the computing environment, to provide information to the user; and a plurality of algorithms selectively executed based on at least a portion of the
20 received information, wherein any one of these algorithms analyzes at least a portion of the received information and generates output information, and preferably wherein the output information is communicated via the output device. The computing environment preferably further comprises a communications network; a server connected to the network; and a client connected to the network, wherein the client is part of a client-
25 server architecture and typically is an application that runs on a personal computer or workstation and relies on a server to perform some operations (see Nath, 1995, The Guide To SQL Server, 2nd ed., Addison-Wesley Publishing Co.).

The computing environment of the present invention is advantageously implemented using any multipurpose computer system including those generally referred
30 to as personal computers and mini-computers. Such a computer system will include means for processing input information such as at least one central processor, for example an Intel® processor (including Pentium® Pentium® II, Celeron™, Pentium® II3,

Pentium® 4 or the like), or Motorola processor (for example, a PowerPC G3 or PowerPC G4 microprocessor capable of running at speeds up to 533 MHz or higher); a storage device, such as a hard disk, for storing information related to CD40, NEMO and/or CYLD polypeptides and/or compounds that alter the binding of NEMO and CYLD (or signaling through CD40); and means for receiving input information. Those of skill in the art recognize that computer technology is changing at a rapid rate; accordingly, new, improved versions of processors are comprehended herein.

The processor, which comprises and/or accesses memory units of the computer system, is programmed to perform analyses of information related to the CD40, NEMO and/or CYLD polypeptides and/or compounds that modulate the binding of NEMO and CYLD (or signaling through CD40). This programming may be permanent, as in the case where the processor is a dedicated PROM (programmable read-only memory) or EEPROM (electrically erasable programmable read-only memory), or it may be transient in which case the programming instructions are loaded from the storage device or from a floppy diskette or other transportable computer-readable media. The computing environment further preferably comprises a user interface such as a Unix/X-Window interface, a Microsoft Windows interface, or a Macintosh operating system interface.

Preferably, the computing environment further includes an optical disk for storing data, a printer for providing a hard copy of the data, and a monitor or video display unit to facilitate user input of information and to display both input and output information. The output information may be output from the processor within the computer system in print form using a printer; on a video display unit; or via a communications link or network to another processor or client application.

The following examples are intended to illustrate various embodiments of the invention, and should not be construed to limit the invention.

EXAMPLE 1

This example describes a gene promoter/reporter system based on the human Interleukin-8 (IL-8) promoter used to analyze the activation of gene transcription in vivo. Other NF-kappaB-responsive promoters besides IL-8 could be used including a minimal promoter element comprising NF-kappaB consensus binding sites. The induction of human IL-8 gene transcription by the cytokines Interleukin-1 (IL-1) or tumor necrosis

factor-alpha (TNF- α) is known to be dependent upon intact NF-kappaB and NF-IL-6 transcription factor binding sites. Fusion of the cytokine-responsive IL-8 promoter with a cDNA encoding the murine IL-4 receptor (mIL-4R) allows measurement of promoter activation by detection of the heterologous reporter protein (mIL-4R) on the cell surface of transfected cells. Other detectable moieties may be used, including any protein or peptide that is detectable by a selected assay and is not present on or in the cells under other conditions (for example, luciferase or human IL-2 receptor).

Human kidney epithelial cells (293/EBNA) are transfected (via the DEAE/DEXTRAN method) with a plasmid encoding the reporter/promoter construct (referred to as pIL-8rep), and cultured under conditions promoting viability. If CD40 activation is necessary for NEMO/CYLD association, 293 cells are transfected with plasmids encoding CD40. Alternatively, the NF-kappaB responsive promoter is introduced (by transfection) into cells that express endogenous CD40 (for example, 70Z/3, WEHI-231, or RAW 264.7 cell-lines). Stimulation of CD40 may be accomplished via addition of soluble CD40L, agonistic antibodies to CD40, or by cotransfection with the transmembrane form of CD40L; use of soluble CD40L is preferred.

The transfected cells are contacted with compounds to be tested. If a compound binds NEMO or CYLD, and inhibits the interaction of these two proteins, NF-kappaB will remain sequestered and unable to activate the IL-8 promoter. As a result, there will be no mIL-4R present on the surface of cells that have been contacted with an effective antagonist. The presence or absence of the mIL-4 receptor is detected by a radioimmunoassay (RIA) or other suitable assay.

EXAMPLE 2

This example illustrates the association of NEMO with CYLD. Interaction of NEMO with CYLD is demonstrated by co-immunoprecipitation assays essentially as described by Hsu et al. (*Cell* 84:299; 1996). Briefly, 293/EBNA cells are co-transfected with plasmids that direct the synthesis of NEMO and epitope-tagged CYLD (or CYLD and epitope-tagged NEMO). Other cells may also be used, including cells that constitutively express NEMO and/or CYLD (for example, 70Z/3 cells). Two days after transfection, cells are lysed (for example, in a buffer containing 0.5% NP-40 and labeled (for example, with biotin-ester). NEMO and proteins associated with NEMO are immunoprecipitated with anti-NEMO (or anti-CYLD), washed extensively, resolved by

electrophoretic separation on a 6-10% SDS polyacrylamide gel and electrophoretically transferred to a nitrocellulose membrane for Western blotting. The association of NEMO with CYLD is visualized by probing the membrane with an antibody that specifically recognizes the tag.

5

EXAMPLE 3

This example describes a yeast two-hybrid screening assay that is useful in screening compounds for the ability to modulate the binding of NEMO and CYLD. Yeast comprising (1) an expression cassette encoding a GAL4 DNA binding domain (or
10 GAL4 activator domain) fused to a binding fragment of NEMO capable of binding to a CYLD polypeptide, (2) an expression cassette encoding a GAL4 DNA activator domain (or GAL4 binding domain, respectively) fused to a binding fragment of CYLD capable of binding to a NEMO polypeptide, and (3) a reporter gene (e.g., beta-galactosidase) comprising a cis-linked GAL4 transcriptional response element can be used for agent
15 screening. Such yeast are incubated with a test agent or the appropriate control(s) under conditions promoting expression of the reporter gene in the absence of an inhibitor, and expression of the reporter is determined. The capacity of the agent to modulate expression of the reporter gene as compared to a control culture identifies the agent as a candidate modulatory agent.

20

EXAMPLE 4

This example illustrates the preparation of monoclonal antibodies against NEMO or CYLD. Preparations of purified NEMO or CYLD, for example, or transfected cells expressing high levels of NEMO or CYLD, are employed to generate monoclonal
25 antibodies against NEMO or CYLD using conventional techniques, such as those disclosed in U.S. Pat. No. 4,411,993, incorporated herein by reference. DNA encoding NEMO or CYLD can also be used as an immunogen, for example, as reviewed by Pardoll and Beckerleg in Immunity 3: 165, 1995. Such antibodies are likely to be useful in interfering with NEMO/CYLD binding (antagonistic or blocking antibodies), as
30 components of diagnostic or research assays for NEMO or CYLD activity, or in affinity purification of NEMO or CYLD.

To immunize rodents, NEMO or CYLD immunogen is emulsified in an adjuvant (such as complete or incomplete Freund's adjuvant, alum, or another adjuvant, such as

Ribi adjuvant R700 (Ribi, Hamilton, Mont.), and injected in amounts ranging from 10-100 µg subcutaneously into a selected rodent, for example, BALB/c mice or Lewis rats. DNA may be given intradermally (Raz et al., *Proc. Natl. Acad. Sci. USA* 91: 9519, 1994) or intramuscularly (Wang et al., *Proc. Natl. Acad. Sci. USA* 90: 4156, 1993); saline has
5 been found to be a suitable diluent for DNA-based antigens. Ten days to three weeks days later, the immunized animals are boosted with additional immunogen and periodically boosted thereafter on a weekly, biweekly or every third week immunization schedule.

Serum samples are periodically taken by retro-orbital bleeding or tail-tip excision for testing by dot-blot assay (antibody sandwich), ELISA (enzyme-linked immunosorbent
10 assay), immunoprecipitation, or other suitable assays, including FACS analysis. Following detection of an appropriate antibody titer, positive animals are given an intravenous injection of antigen in saline. Three to four days later, the animals are sacrificed, splenocytes harvested, and fused to a murine myeloma cell line (e.g., NS1 or preferably Ag 8.653 [ATCC CRL 1580]). Hybridoma cell lines generated by this
15 procedure are plated in multiple microtiter plates in a selective medium (for example, one containing hypoxanthine, aminopterin, and thymidine, or HAT) to inhibit proliferation of non-fused cells, myeloma-myeloma hybrids, and splenocyte-splenocyte hybrids.

Hybridoma clones thus generated can be screened by ELISA for reactivity with NEMO or CYLD, for example, by adaptations of the techniques disclosed by Engvall et al., *Immunochem.* 8: 871 (1971) and in U.S. Pat. No. 4,703,004. A preferred screening
20 technique is the antibody capture technique described by Beckman et al., *J. Immunol.* 144: 4212 (1990). Positive clones are then injected into the peritoneal cavities of syngeneic rodents to produce ascites containing high concentrations (>1 mg/ml) of monoclonal antibody. The resulting monoclonal antibody can be purified by ammonium sulfate precipitation followed by gel exclusion chromatography. Alternatively, affinity
25 chromatography based upon binding of antibody to protein A or protein G can also be used, as can affinity chromatography based upon binding to NEMO or CYLD protein.

Techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, *Science* 242:423, 1988; Huston et al., *Proc. Natl. Acad. Sci. USA*
30 85:5879, 1988; and Ward et al., *Nature* 334:544, 1989) can also be adapted to produce single chain antibodies against NEMO or CYLD. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge,

resulting in a single chain polypeptide. Such single chain antibodies can be useful intracellularly (i.e., as 'intrabodies'), for example as described by Marasco *et al.* (*J. Immunol. Methods* 231:223-238, 1999) for genetic therapy in HIV infection. Intrabodies that bind NEMO or CYLD and inhibit the interaction thereof will be useful in
5 downregulating specific CD40-signaling response.

EXAMPLE 5

In accordance with the present invention, a series of oligonucleotides are designed to target different regions of the NEMO or CYLD mRNA molecule, using the nucleotide
10 sequence of SEQ ID Nos:1 or 3, respectively, as the basis for the design of the oligonucleotides. The oligonucleotides are selected to be approximately 10, 12, 15, 18, or more preferably 20 nucleotide residues in length, and to have a predicted hybridization temperature that is at least 37 degrees C. Preferably, the oligonucleotides are selected so that some will hybridize toward the 5' region of the mRNA molecule, others will
15 hybridize to the coding region, and still others will hybridize to the 3' region of the mRNA molecule.

The oligonucleotides may be oligodeoxynucleotides, with phosphorothioate backbones (internucleoside linkages) throughout, or may have a variety of different types of internucleoside linkages. Generally, methods for the preparation, purification, and use
20 of a variety of chemically modified oligonucleotides are described in U.S. Patent No. 5,948,680. As specific examples, the following types of nucleoside phosphoramidites may be used in oligonucleotide synthesis: deoxy and 2'-alkoxy amidites; 2'-fluoro amidites such as 2'-fluorodeoxyadenosine amidites, 2'-fluorodeoxyguanosine, 2'-fluorouridine, and 2'-fluorodeoxycytidine; 2'-O-(2-methoxyethyl)-modified amidites such
25 as 2,2'-anhydro[1-(beta-D-arabino-furanosyl)-5-methyluridine], 2'-O-methoxyethyl-5-methyluridine, 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine, 3'-O-acetyl-2'-O-methoxy-ethyl-5'-O-dimethoxy-trityl-5-methyluridine, 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine, 2'-O-methoxyethyl-5'-O-dimethoxy-trityl-5-methylcytidine, N4-benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-
30 cytidine, and N4-benzoyl-2'-O-methoxyethyl-5'-O-di-methoxytrityl-5-methylcytidine-3'-amidite; 2'-O-(aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites such as 2'-(dimethylaminooxyethoxy) nucleoside amidites, 5'-O-tert-butyl-diphenylsilyl-O²-2'-anhydro-5-methyluridine, 5'-O-tert-butyl-diphenylsilyl-2'-O-(2-

hydroxyethyl)-5-methyluridine, 2'-O-[(2-phthalimidoxymethyl)-5'-*t*-butyl-diphenyl-silyl-5-methyluridine, 5'-O-*tert*-butyl-diphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine, 5'-O-*tert*-butyl-diphenylsilyl-2'-O-[N,N-dimethyl-aminooxyethyl]-5-methyluridine, 2'-O-(dimethyl-aminooxy-ethyl)-5-methyluridine, 5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine, and 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropyl-phosphor-amidite]; and 2'-(aminooxyethoxy) nucleoside amidites such as N2-isobutyryl-6-O-diphenyl-carbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)-guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

10 Modified oligonucleosides may also be used in oligonucleotide synthesis, for example methylenemethylimino-linked oligonucleosides, also called MMI-linked oligonucleosides; methylene-dimethylhydrazo-linked oligonucleosides, also called MDH-linked oligonucleosides; methylene-carbonylamino-linked oligonucleosides, also called amide-3-linked oligonucleosides; and methylene-aminocarbonyl-linked oligonucleosides, 15 also called amide-4-linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages, which are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289. Formacetal- and thioformacetal-linked oligonucleosides may also be used and are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564; and ethylene oxide 20 linked oligonucleosides may also be used and are prepared as described in U.S. Pat. No. 5,223,618. Peptide nucleic acids (PNAs) may be used as in the same manner as the oligonucleotides described above, and are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996, 4, 5-23; and U.S. Pat. 25 Nos. 5,539,082, 5,700,922, and 5,719,262.

Chimeric oligonucleotides, oligonucleosides, or mixed oligonucleotides-oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" 30 segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers". Some examples of different types of chimeric

oligonucleotides are: [2'-O-Me]--[2'-deoxy]--[2'-O-Me] chimeric phosphorothioate oligonucleotides, [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides, and [2'-O-(2-methoxy-ethyl)phosphodiester]--[2'-deoxyphosphoro-thioate]--[2'-O-(2-methoxyethyl)-phosphodiester] chimeric oligonucleotides, all of which may be prepared according to U.S. Patent No. 5,948,680. In one preferred embodiment, chimeric oligonucleotides ("gapmers") 18 nucleotides in length are utilized, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by four-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines. Other chimeric oligonucleotides, chimeric oligonucleosides, and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065.

Oligonucleotides are preferably synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. The concentration of oligonucleotide in each well is assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products is evaluated by capillary electrophoresis, and base and backbone composition is confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy.

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. Cells are routinely maintained for up to 10 passages as recommended by the supplier. When cells reach 80% to 90% confluency, they are treated with oligonucleotide. For cells grown in 96-well plates, wells are washed once with 200 microliters OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then treated with 130 microliters of OPTI-MEM-1 containing 3.75 g/mL LIPOFECTIN (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16 hours after oligonucleotide treatment. Preferably, the effect of several different oligonucleotides should be tested simultaneously, where the oligonucleotides hybridize to different

portions of the target nucleic acid molecules, in order to identify the oligonucleotides producing the greatest degree of inhibition of expression of the target nucleic acid.

Antisense modulation of NEMO or CYLD nucleic acid expression can be assayed in a variety of ways known in the art. For example, NEMO or CYLD mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation and Northern blot analysis are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1996.

Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer's instructions. This fluorescence detection system allows high-throughput quantitation of PCR products. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 3' end of the probe.

When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from

untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples. Other methods of quantitative PCR analysis are also known in the art.

NEMO or CYLD protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA, or fluorescence-activated cell sorting (FACS). Antibodies directed to NEMO or CYLD polypeptides can be prepared via conventional antibody generation methods such as those described herein. Immunoprecipitation methods, Western blot (immunoblot) analysis, and enzyme-linked immunosorbent assays (ELISA) are standard in the art (see, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, 10.8.1-10.8.21, and 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

EXAMPLE 6

This example describes a mammalian two-hybrid screening assay (substantially as described in Shioda et al., *Proc. Natl. Acad. Sci. USA* 97:5220, 2000) that is useful in screening compounds for the ability to modulate the binding of NEMO and CYLD. For this assay, CV-1/EBNA-1 monkey kidney epithelial cells expressing Epstein-Barr virus nuclear antigen 1 (EBNA-1) are stably transfected with a reporter plasmid for GAL4-dependent expression of the green fluorescent protein (GFP). Clones that express GFP when transfected transiently with transcriptional activators fused to GAL4 DNA-binding domain with minimal background GFP expression are identified.

Useful clones are then transfected stably with a model bait (for example, NEMO or CYLD) and prey (CYLD or NEMO, respectively); under conditions in which both NEMO and CYLD are expressed and allowed to bind to each other, the cells will express GFP and can be readily identified by green fluorescence in cell culture. Such cells are incubated with a test agent or the appropriate control(s) and the capacity of the agent to modulate expression of GFP as compared to a control culture is determined. Those of skill in the art will be able to select other reporter genes as desired.

EXAMPLE 7

In this assay, test molecules capable of modulating an activity associated with CD40 signaling are identified by assessing the ability of B cells to undergo immunoglobulin class switching, and/or the ability of peripheral blood mononuclear cells

(PBMCs) to synthesize IL-12 and/or TNF-alpha. Human peripheral blood mononuclear cells (PBMC) are isolated from peripheral blood from normal volunteers by density gradient centrifugation over Histopaque® (Sigma, St. Louis, MO). T cell-depleted preparations of cells (E-) are obtained by removing T cells by rosetting with 2-aminoethylisothiuronium bromide-treated SRBC (sheep red blood cells) and further
5 density gradient centrifugation over Histopaque®. Alternatively, B cells are selectively isolated using anti CD19-coated magnetic beads (Dynal, Lake Success, NY).

B cell assays are conducted in RPMI media with added 10% heat-inactivated fetal bovine serum (FBS) at 37°C in a 10% CO₂ atmosphere. Cells (approximately 1 x 10⁶
10 cells per well for observation of markers; approximately 1 x 10⁵ cells per well for detection of immunoglobulin in supernatant fluid) are cultured in the presence of 2.5 micrograms/ml of soluble, trimeric CD40L (described in the Armitage patents), for seven to eight days. Immunoglobulin concentrations (IgG, IgA) in the supernatant fluid are determined by specific ELISA; cells are monitored for the expression of CD54 by flow
15 cytometry.

PBMC assays are conducted in RPMI 1640 complete medium. Approximately 2 x 10⁶ cells per well are cultured in the presence of 2.5 micrograms/ml of soluble, trimeric CD40L (described in the Armitage patents), for 36 to 48 hours. Concentration of IL-12 and/or TNF-alpha in the supernatant fluid are determined by specific ELISA; cells are
20 monitored for the expression of molecules indicative of activation by flow cytometry.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the
25 foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method for identifying compounds that alter one or more biological activities of CD40, comprising:

(a) mixing a test compound with a polypeptide selected from the group consisting of (i) a NEMO polypeptide comprising amino acids 287 through 419 SEQ ID NO:2, (ii) a fragment of a NEMO polypeptide according to (i) that is capable of binding a CYLD polypeptide according to SEQ ID NO:4 or fragment or variant thereof, and (iii) variants of the NEMO polypeptides of (i) and (ii); and

(b) determining whether the test compound alters the ability of NEMO to bind CYLD.

2. A method for identifying compounds that inhibit binding of NEMO and CYLD comprising:

(a) mixing a test compound with a polypeptide selected from the group consisting of (i) a NEMO polypeptide comprising amino acids 287 through 419 SEQ ID NO:2, (ii) a fragment of a NEMO polypeptide according to (i) that is capable of binding a CYLD polypeptide according to SEQ ID NO:4, and (iii) variants of the NEMO polypeptides of (i) and (ii), and a binding partner of said NEMO polypeptide selected from the group consisting of (iv) a CYLD polypeptide according to SEQ ID NO:4, (v) a fragment of a CYLD polypeptide according to SEQ ID NO:4 that is capable of binding a NEMO polypeptide of (i), (ii), or (iii), and (vi) a variant of the CYLD polypeptides of (iv) and (v) that is capable of binding a NEMO polypeptide of (i), (ii), or (iii); and

(b) determining whether the test compound inhibits the binding activity of said NEMO and CYLD polypeptides.

3. A method for producing information comprising the identity of a compound that alters one or more biological activities of CD40, the method comprising identifying one or more compounds that alter NEMO/CYLD binding activity.

4. The method of claim 3 wherein the compound decreases the binding of NEMO to CYLD.

5. The method of claim 3 wherein the compound increases the binding of NEMO to CYLD.

6. Information produced according to the method of claim 3, said information comprising the identity of a compound that alters the binding of NEMO to CYLD.

7. The information of claim 6 wherein the information is embodied in a storage medium selected from the group consisting of the brain of a living organism, paper, magnetic tape, optical tape, floppy disks, compact disks, computer system hard drives, and computer memory units.

8. A database comprising the information of claim 7.

9. The information of claim 7 wherein the information is embodied in a computer-readable medium.

10. The information of claim 7 wherein the information is embodied in a human-readable medium.

11. A computer system comprising a database containing records pertaining to a plurality of compounds, wherein the records comprise results of an assay according to claim 1, and a user interface allowing a user to access information regarding the plurality of compounds.

12. A computer system comprising a database containing records pertaining to a plurality of compounds, wherein the records comprise results of an assay according to claim 2, and a user interface allowing a user to access information regarding the plurality of compounds.

13. A computer system for storing and retrieving data on a plurality of compounds, the computer system comprising:

(a) input means for entering data for the compounds into a storage medium;

a processor for creating an individual record for each compound, the processor assigning specific identifying values for each compound;

(b) means for selecting one or more of the records based on results in an assay;

and

(c) means for transmitting information in the record or records to an output device to produce a report.

14. The system of claim 13 further comprising a video display unit.

15. The computer system of claim 13 where the report is in human-readable form.

16. The computer system of claim 14 where the report is in human-readable form.

17. A method of using the computer system of claim 13 to select one or more compounds for testing from a plurality of compounds having records stored in a database, the method comprising: displaying a list of said records or a field for entering information identifying one or more of said records; and selecting one or more of the records from the list or the record or records identified by entering information in the field.

18. A method of operating a computer system for analyzing compounds that modulate the interaction of NEMO and CYLD, the method comprising:

(a) entering data relating to a plurality of compounds into a storage medium; processing the data to create an individual record for each compound;

(b) testing compounds for the ability to modulate binding of NEMO to CYLD;

and

(c) communicating results from the testing into the storage medium such that results for each compound are associated with the individual record for that compound.

19. The method of claim 18 wherein the storage medium comprises one or more computer memory units.

20. The method of claim 19 wherein the computer system further comprises a video display unit.

21. A database comprising records generated according to the method of claim 18.

22. A method of selecting compounds that alter one or more biological activities of CD40, comprising compiling a database according to claim 21, analyzing the testing results, and selecting one or more compounds.

23. A method for increasing one or more biological activities of CD40 comprising providing at least one compound selected according to the method of claim 22.

24. A method for decreasing one or more biological activities of CD40 comprising providing at least one compound selected according to the method of claim 22.




Figure 1

BEST AVAILABLE COPY

SEQUENCE LISTING

<110> IMMUNEX CORPORATION
Derry, Jonathan M. J.
Fanslow III, William
Dougall, William C.

<120> SCREENING ASSAYS FOR AGONISTS OR ANTAGONISTS OF CD40 SIGNALING

<130> 3198-WO

<140> --to be assigned--
<141> 2002-05-07

<150> 09/851,673
<151> 2001-05-08

<160> 4

<170> PatentIn version 3.1

<210> 1
<211> 1994
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (149)..(1405)
<223>

<400> 1
ggcacgagca tggcccttgt gatccaggtg gggaaactaa ggcccagaga agtgaggacc 60
ccgcagacta tcaatcccag tctcttcccc tcaactccctg tgaagctctc cagcatcatc 120
gagggtcccat cagcccttgc cctgttgg atg aat agg cac ctc tgg aag agc 172
Met Asn Arg His Leu Trp Lys Ser
1 5
caa ctg tgt gag atg gtg cag ccc agt ggt ggc ccg gca gca gat cag 220
Gln Leu Cys Glu Met Val Gln Pro Ser Gly Gly Pro Ala Ala Asp Gln
10 15 20
gac gta ctg ggc gaa gag tct cct ctg ggg aag cca gcc atg ctg cac 268
Asp Val Leu Gly Glu Glu Ser Pro Leu Gly Lys Pro Ala Met Leu His
25 30 35 40
ctg cct tca gaa cag ggc gct cct gag acc ctc cag cgc tgc ctg gag 316
Leu Pro Ser Glu Gln Gly Ala Pro Glu Thr Leu Gln Arg Cys Leu Glu
45 50 55
gag aat caa gag ctc cga gat gcc atc cgg cag agc aac cag att ctg 364
Glu Asn Gln Glu Leu Arg Asp Ala Ile Arg Gln Ser Asn Gln Ile Leu
60 65 70

cgg gag cgc tgc gag gag ctt ctg cat ttc caa gcc agc cag agg gag Arg Glu Arg Cys Glu Glu Leu Leu His Phe Gln Ala Ser Gln Arg Glu 75 80 85	412
gag aag gag ttc ctc atg tgc aag ttc cag gag gcc agg aaa ctg gtg Glu Lys Glu Phe Leu Met Cys Lys Phe Gln Glu Ala Arg Lys Leu Val 90 95 100	460
gag aga ctc ggc ctg gag aag ctc gat ctg aag agg cag aag gag cag Glu Arg Leu Gly Leu Glu Lys Leu Asp Leu Lys Arg Gln Lys Glu Gln 105 110 115 120	508
gct ctg cgg gag gtg gag cac ctg aag aga tgc cag cag cag atg gct Ala Leu Arg Glu Val Glu His Leu Lys Arg Cys Gln Gln Gln Met Ala 125 130 135	556
gag gac aag gcc tct gtg aaa gcc cag gtg acg tcc ttg ctc ggg gag Glu Asp Lys Ala Ser Val Lys Ala Gln Val Thr Ser Leu Leu Gly Glu 140 145 150	604
ctg cag gag agc cag agt cgc ttg gag gct gcc act aag gaa tgc cag Leu Gln Glu Ser Gln Ser Arg Leu Glu Ala Ala Thr Lys Glu Cys Gln 155 160 165	652
gct ctg gag ggt cgg gcc cgg gcg gcc agc gag cag gcg cgg cag ctg Ala Leu Glu Gly Arg Ala Arg Ala Ala Ser Glu Gln Ala Arg Gln Leu 170 175 180	700
gag agt gag cgc gag gcg ctg cag cag cag cac agc gtg cag gtg gac Glu Ser Glu Arg Glu Ala Leu Gln Gln Gln His Ser Val Gln Val Asp 185 190 195 200	748
cag ctg cgc atg cag ggc cag agc gtg gag gcc gcg ctc cgc atg gag Gln Leu Arg Met Gln Gly Gln Ser Val Glu Ala Ala Leu Arg Met Glu 205 210 215	796
cgc cag gcc gcc tcg gag gag aag agg aag ctg gcc cag ttg cag gtg Arg Gln Ala Ala Ser Glu Glu Lys Arg Lys Leu Ala Gln Leu Gln Val 220 225 230	844
gcc tat cac cag ctc ttc caa gaa tac gac aac cac atc aag agc agc Ala Tyr His Gln Leu Phe Gln Glu Tyr Asp Asn His Ile Lys Ser Ser 235 240 245	892
gtg gtg ggc agt gag cgg aag cga gga atg cag ctg gaa gat ctc aaa Val Val Gly Ser Glu Arg Lys Arg Gly Met Gln Leu Glu Asp Leu Lys 250 255 260	940
cag cag ctc cag cag gcc gag gag gcc ctg gtg gcc aaa cag gag gtg Gln Gln Leu Gln Gln Ala Glu Glu Ala Leu Val Ala Lys Gln Glu Val 265 270 275 280	988
atc gat aag ctg aag gag gag gcc gag cag cac aag att gtg atg gag Ile Asp Lys Leu Lys Glu Glu Ala Glu Gln His Lys Ile Val Met Glu 285 290 295	1036

acc gtt ccg gtg ctg aag gcc cag gcg gat atc tac aag gcg gac ttc 1084
 Thr Val Pro Val Leu Lys Ala Gln Ala Asp Ile Tyr Lys Ala Asp Phe
 300 305 310

cag gct gag agg cag gcc cgg gag aag ctg gcc gag aag aag gag ctc 1132
 Gln Ala Glu Arg Gln Ala Arg Glu Lys Leu Ala Glu Lys Lys Glu Leu
 315 320 325

ctg cag gag cag ctg gag cag ctg cag agg gag tac agc aaa ctg aag 1180
 Leu Gln Glu Gln Leu Glu Gln Leu Gln Arg Glu Tyr Ser Lys Leu Lys
 330 335 340

gcc agc tgt cag gag tcg gcc agg atc gag gac atg agg aag cgg cat 1228
 Ala Ser Cys Gln Glu Ser Ala Arg Ile Glu Asp Met Arg Lys Arg His
 345 350 355 360

gtc gag gtc tcc cag gcc ccc ttg ccc ccc gcc cct gcc tac ctc tcc 1276
 Val Glu Val Ser Gln Ala Pro Leu Pro Pro Ala Pro Ala Tyr Leu Ser
 365 370 375

tct ccc ctg gcc ctg ccc agc cag agg agg agc ccc ccc gag gag cca 1324
 Ser Pro Leu Ala Leu Pro Ser Gln Arg Arg Ser Pro Pro Glu Glu Pro
 380 385 390

cct gac ttc tgc tgt ccc aag tgc cag tat cag gcc cct gat atg gac 1372
 Pro Asp Phe Cys Cys Pro Lys Cys Gln Tyr Gln Ala Pro Asp Met Asp
 395 400 405

acc ctg cag ata cat gtc atg gag tgc att gag tagggccggc cagtgcgaagg 1425
 Thr Leu Gln Ile His Val Met Glu Cys Ile Glu
 410 415

ccactgcctg cccgaggacg tgcccggggac cgtgcagtct gcgctttcct ctcccgcctg 1485

cctagcccag gatgaagggc tgggtggcca caactgggat gccacctgga gccccaccca 1545

ggagctggcc gcggcacctt acgcttcagc tgttgatccg ctggtcccct cttttgggggt 1605

agatgcggcc ccgatcaggc ctgactcget gctctttttg ttcccttctg tctgctcgaa 1665

ccacttgccct cgggctaate cctccctctt cctccacccg gcaactgggga agtcaagaat 1725

ggggcctggg gctctcaggg agaactgctt cccctggcag agctgggtgg cagctcttcc 1785

tcccaccgga caccgacccg cccgcgcgtg tgccctggga gtgctgccct cttaccatgc 1845

acacgggtgc tctccttttg ggctgcattg tattccattt tgcagccaga ccgatgtgta 1905

tttaaccagt cactattgat ggacatttgg gttgtttccc atctttttgt taccataaat 1965

aatggcatag taaaaaaaaa aaaaaaaaaa 1994

<210> 2
 <211> 419

<212> PRT

<213> Homo sapiens

<400> 2

Met Asn Arg His Leu Trp Lys Ser Gln Leu Cys Glu Met Val Gln Pro
 1 5 10 15

Ser Gly Gly Pro Ala Ala Asp Gln Asp Val Leu Gly Glu Glu Ser Pro
 20 25 30

Leu Gly Lys Pro Ala Met Leu His Leu Pro Ser Glu Gln Gly Ala Pro
 35 40 45

Glu Thr Leu Gln Arg Cys Leu Glu Glu Asn Gln Glu Leu Arg Asp Ala
 50 55 60

Ile Arg Gln Ser Asn Gln Ile Leu Arg Glu Arg Cys Glu Glu Leu Leu
 65 70 75 80

His Phe Gln Ala Ser Gln Arg Glu Glu Lys Glu Phe Leu Met Cys Lys
 85 90 95

Phe Gln Glu Ala Arg Lys Leu Val Glu Arg Leu Gly Leu Glu Lys Leu
 100 105 110

Asp Leu Lys Arg Gln Lys Glu Gln Ala Leu Arg Glu Val Glu His Leu
 115 120 125

Lys Arg Cys Gln Gln Gln Met Ala Glu Asp Lys Ala Ser Val Lys Ala
 130 135 140

Gln Val Thr Ser Leu Leu Gly Glu Leu Gln Glu Ser Gln Ser Arg Leu
 145 150 155 160

Glu Ala Ala Thr Lys Glu Cys Gln Ala Leu Glu Gly Arg Ala Arg Ala
 165 170 175

Ala Ser Glu Gln Ala Arg Gln Leu Glu Ser Glu Arg Glu Ala Leu Gln
 180 185 190

Gln Gln His Ser Val Gln Val Asp Gln Leu Arg Met Gln Gly Gln Ser
 195 200 205

Val Glu Ala Ala Leu Arg Met Glu Arg Gln Ala Ala Ser Glu Glu Lys
 210 215 220

Arg Lys Leu Ala Gln Leu Gln Val Ala Tyr His Gln Leu Phe Gln Glu
 225 230 235 240

Tyr Asp Asn His Ile Lys Ser Ser Val Val Gly Ser Glu Arg Lys Arg
 245 250 255

Gly Met Gln Leu Glu Asp Leu Lys Gln Gln Leu Gln Gln Ala Glu Glu
 260 265 270

Ala Leu Val Ala Lys Gln Glu Val Ile Asp Lys Leu Lys Glu Glu Ala
 275 280 285

Glu Gln His Lys Ile Val Met Glu Thr Val Pro Val Leu Lys Ala Gln
 290 295 300

Ala Asp Ile Tyr Lys Ala Asp Phe Gln Ala Glu Arg Gln Ala Arg Glu
 305 310 315 320

Lys Leu Ala Glu Lys Lys Glu Leu Leu Gln Glu Gln Leu Glu Gln Leu
 325 330 335

Gln Arg Glu Tyr Ser Lys Leu Lys Ala Ser Cys Gln Glu Ser Ala Arg
 340 345 350

Ile Glu Asp Met Arg Lys Arg His Val Glu Val Ser Gln Ala Pro Leu
 355 360 365

Pro Pro Ala Pro Ala Tyr Leu Ser Ser Pro Leu Ala Leu Pro Ser Gln
 370 375 380

Arg Arg Ser Pro Pro Glu Glu Pro Pro Asp Phe Cys Cys Pro Lys Cys
 385 390 395 400

Gln Tyr Gln Ala Pro Asp Met Asp Thr Leu Gln Ile His Val Met Glu
 405 410 415

Cys Ile Glu

```
<220>
<221> CDS
<222> (392) .. (3262)
<223>
```

6

agt	aaa	ggc	ctc	caa	ata	gac	gtg	ggc	tgt	cct	gtg	aaa	gta	cag	ctg	796
Ser	Lys	Gly	Leu	Gln	Ile	Asp	Val	Gly	Cys	Pro	Val	Lys	Val	Gln	Leu	
120					125					130					135	
aga	tct	ggg	gaa	gaa	aaa	ttt	cct	gga	gtt	gta	cgc	ttc	aga	gga	ccc	844
Arg	Ser	Gly	Glu	Glu	Lys	Phe	Pro	Gly	Val	Val	Arg	Phe	Arg	Gly	Pro	
				140					145					150		
ctg	tta	gca	gag	agg	aca	gtc	tcc	gga	ata	ttc	ttt	gga	gtt	gaa	ttg	892
Leu	Leu	Ala	Glu	Arg	Thr	Val	Ser	Gly	Ile	Phe	Phe	Gly	Val	Glu	Leu	
			155					160					165			
ctg	gaa	gaa	ggg	cgt	ggg	caa	ggg	ttc	act	gac	ggg	gtg	tac	caa	ggg	940
Leu	Glu	Glu	Gly	Arg	Gly	Gln	Gly	Phe	Thr	Asp	Gly	Val	Tyr	Gln	Gly	
		170					175					180				
aaa	cag	ctt	ttt	cag	tgt	gat	gaa	gat	tgt	ggc	gtg	ttt	gtt	gca	ttg	988
Lys	Gln	Leu	Phe	Gln	Cys	Asp	Glu	Asp	Cys	Gly	Val	Phe	Val	Ala	Leu	
	185					190					195					
gac	aag	cta	gaa	ctc	ata	gaa	gat	gat	gac	act	gca	ttg	gaa	agt	gat	1036
Asp	Lys	Leu	Glu	Leu	Ile	Glu	Asp	Asp	Asp	Thr	Ala	Leu	Glu	Ser	Asp	
200					205					210					215	
tac	gca	ggg	cct	ggg	gac	aca	atg	cag	gtc	gaa	ctt	cct	cct	ttg	gaa	1084
Tyr	Ala	Gly	Pro	Gly	Asp	Thr	Met	Gln	Val	Glu	Leu	Pro	Pro	Leu	Glu	
				220					225					230		
ata	aac	tcc	aga	gtt	tct	ttg	aag	gtt	gga	gaa	aca	ata	gaa	tct	gga	1132
Ile	Asn	Ser	Arg	Val	Ser	Leu	Lys	Val	Gly	Glu	Thr	Ile	Glu	Ser	Gly	
			235					240					245			
aca	gtt	ata	ttc	tgt	gat	gtt	ttg	cca	gga	aaa	gaa	agc	tta	gga	tat	1180
Thr	Val	Ile	Phe	Cys	Asp	Val	Leu	Pro	Gly	Lys	Glu	Ser	Leu	Gly	Tyr	
		250					255					260				
ttt	gtt	ggg	gtg	gac	atg	gat	aac	cct	att	ggc	aac	tgg	gat	gga	aga	1228
Phe	Val	Gly	Val	Asp	Met	Asp	Asn	Pro	Ile	Gly	Asn	Trp	Asp	Gly	Arg	
	265					270					275					
ttt	gat	gga	gtg	cag	ctt	tgt	agt	ttt	gcg	tgt	gtt	gaa	agt	aca	att	1276
Phe	Asp	Gly	Val	Gln	Leu	Cys	Ser	Phe	Ala	Cys	Val	Glu	Ser	Thr	Ile	
280					285					290					295	
cta	ttg	cac	atc	aat	gat	atc	atc	cca	gct	tta	tca	gag	agt	gtg	acg	1324
Leu	Leu	His	Ile	Asn	Asp	Ile	Ile	Pro	Ala	Leu	Ser	Glu	Ser	Val	Thr	
				300					305					310		
cag	gaa	agg	agg	cct	ccc	aaa	ctt	gcc	ttt	atg	tca	aga	ggg	gtt	ggg	1372
Gln	Glu	Arg	Arg	Pro	Pro	Lys	Leu	Ala	Phe	Met	Ser	Arg	Gly	Val	Gly	
			315					320					325			
gac	aaa	ggg	tca	tcc	agt	cat	aat	aaa	cca	aag	gct	aca	gga	tct	acc	1420
Asp	Lys	Gly	Ser	Ser	Ser	His	Asn	Lys	Pro	Lys	Ala	Thr	Gly	Ser	Thr	
		330					335					340				

tca gac cct gga aat aga aac aga tct gaa tta ttt tat acc tta aat	1468
Ser Asp Pro Gly Asn Arg Asn Arg Ser Glu Leu Phe Tyr Thr Leu Asn	
345 350 355	
ggg tct tct gtt gac tca caa cca caa tcc aaa tca aaa aat aca tgg	1516
Gly Ser Ser Val Asp Ser Gln Pro Gln Ser Lys Ser Lys Asn Thr Trp	
360 365 370 375	
tac att gat gaa gtt gca gaa gac cct gca aaa tct ctt aca gag ata	1564
Tyr Ile Asp Glu Val Ala Glu Asp Pro Ala Lys Ser Leu Thr Glu Ile	
380 385 390	
tct aca gac ttt gac cgt tct tca cca cca ctc cag cct cct cct gtg	1612
Ser Thr Asp Phe Asp Arg Ser Ser Pro Pro Leu Gln Pro Pro Pro Val	
395 400 405	
aac tca ctg acc acc gag aac aga ttc cac tct tta cca ttc agt ctc	1660
Asn Ser Leu Thr Thr Glu Asn Arg Phe His Ser Leu Pro Phe Ser Leu	
410 415 420	
acc aag atg ccc aat acc aat gga agt att ggc cac agt cca ctt tct	1708
Thr Lys Met Pro Asn Thr Asn Gly Ser Ile Gly His Ser Pro Leu Ser	
425 430 435	
ctg tca gcc cag tct gta atg gaa gag cta aac act gca ccc gtc caa	1756
Leu Ser Ala Gln Ser Val Met Glu Glu Leu Asn Thr Ala Pro Val Gln	
440 445 450 455	
gag agt cca ccc ttg gcc atg cct cct ggg aac tca cat ggt cta gaa	1804
Glu Ser Pro Pro Leu Ala Met Pro Pro Gly Asn Ser His Gly Leu Glu	
460 465 470	
gtg ggc tca ttg gct gaa gtt aag gag aac cct cct ttc tat ggg gta	1852
Val Gly Ser Leu Ala Glu Val Lys Glu Asn Pro Pro Phe Tyr Gly Val	
475 480 485	
atc cgt tgg atc ggt cag cca cca gga ctg aat gaa gtg ctc gct gga	1900
Ile Arg Trp Ile Gly Gln Pro Pro Gly Leu Asn Glu Val Leu Ala Gly	
490 495 500	
ctg gaa ctg gaa gat gag tgt gca ggc tgt acg gat gga acc ttc aga	1948
Leu Glu Leu Glu Asp Glu Cys Ala Gly Cys Thr Asp Gly Thr Phe Arg	
505 510 515	
ggc act cgg tat ttc acc tgt gcc ctg aag aag gcg ctg ttt gtg aaa	1996
Gly Thr Arg Tyr Phe Thr Cys Ala Leu Lys Lys Ala Leu Phe Val Lys	
520 525 530 535	
ctg aag agc tgc agg cct gac tct agg ttt gca tca ttg cag ccg gtt	2044
Leu Lys Ser Cys Arg Pro Asp Ser Arg Phe Ala Ser Leu Gln Pro Val	
540 545 550	
tcc aat cag att gag cgc tgt aac tct tta gca ttt gga ggc tac tta	2092
Ser Asn Gln Ile Glu Arg Cys Asn Ser Leu Ala Phe Gly Gly Tyr Leu	
555 560 565	

agt gaa gta gta gaa gaa aat act cca cca aaa atg gaa aaa gaa ggc	2140
Ser Glu Val Val Glu Glu Asn Thr Pro Pro Lys Met Glu Lys Glu Gly	
570 575 580	
ttg gag ata atg att ggg aag aag aaa ggc atc cag ggt cat tac aat	2188
Leu Glu Ile Met Ile Gly Lys Lys Lys Gly Ile Gln Gly His Tyr Asn	
585 590 595	
tct tgt tac tta gac tca acc tta ttc tgc tta ttt gct ttt agt tct	2236
Ser Cys Tyr Leu Asp Ser Thr Leu Phe Cys Leu Phe Ala Phe Ser Ser	
600 605 610 615	
gtt ctg gac act gtg tta ctt aga ccc aaa gaa aag aac gat gta gaa	2284
Val Leu Asp Thr Val Leu Leu Arg Pro Lys Glu Lys Asn Asp Val Glu	
620 625 630	
tat tat agt gaa acc caa gag cta ctg agg aca gaa att gtt aat cct	2332
Tyr Tyr Ser Glu Thr Gln Glu Leu Leu Arg Thr Glu Ile Val Asn Pro	
635 640 645	
ctg aga ata tat gga tat gtg tgt gcc aca aaa att atg aaa ctg agg	2380
Leu Arg Ile Tyr Gly Tyr Val Cys Ala Thr Lys Ile Met Lys Leu Arg	
650 655 660	
aaa ata ctt gaa aag gtg gag gct gca tca gga ttt acc tct gaa gaa	2428
Lys Ile Leu Glu Lys Val Glu Ala Ala Ser Gly Phe Thr Ser Glu Glu	
665 670 675	
aaa gat cct gag gaa ttc ttg aat att ctg ttt cat cat att tta agg	2476
Lys Asp Pro Glu Glu Phe Leu Asn Ile Leu Phe His His Ile Leu Arg	
680 685 690 695	
gta gaa cct ttg cta aaa ata aga tca gca ggt caa aag gta caa gat	2524
Val Glu Pro Leu Leu Lys Ile Arg Ser Ala Gly Gln Lys Val Gln Asp	
700 705 710	
tgt tac ttc tat caa att ttt atg gaa aaa aat gag aaa gtt ggc gtt	2572
Cys Tyr Phe Tyr Gln Ile Phe Met Glu Lys Asn Glu Lys Val Gly Val	
715 720 725	
ccc aca att cag cag ttg tta gaa tgg tct ttt atc aac agt aac ctg	2620
Pro Thr Ile Gln Gln Leu Leu Glu Trp Ser Phe Ile Asn Ser Asn Leu	
730 735 740	
aaa ttt gca gag gca cca tca tgt ctg att att cag atg cct cga ttt	2668
Lys Phe Ala Glu Ala Pro Ser Cys Leu Ile Ile Gln Met Pro Arg Phe	
745 750 755	
gga aaa gac ttt aaa cta ttt aaa aaa att ttt cct tct ctg gaa tta	2716
Gly Lys Asp Phe Lys Leu Phe Lys Lys Ile Phe Pro Ser Leu Glu Leu	
760 765 770 775	
aat ata aca gat tta ctt gaa gac act ccc aga cag tgc cgg ata tgt	2764
Asn Ile Thr Asp Leu Leu Glu Asp Thr Pro Arg Gln Cys Arg Ile Cys	
780 785 790	

gga ggg ctt gca atg tat gag tgt aga gaa tgc tac gac gat ccg gac	2812
Gly Gly Leu Ala Met Tyr Glu Cys Arg Glu Cys Tyr Asp Asp Pro Asp	
795 800 805	
atc tca gct gga aaa atc aag cag ttt tgt aaa acc tgc aac act caa	2860
Ile Ser Ala Gly Lys Ile Lys Gln Phe Cys Lys Thr Cys Asn Thr Gln	
810 815 820	
gtc cac ctt cat ccg aag agg ctg aat cat aaa tat aac cca gtg tca	2908
Val His Leu His Pro Lys Arg Leu Asn His Lys Tyr Asn Pro Val Ser	
825 830 835	
ctt ccc aaa gac tta ccc gac tgg gac tgg aga cac ggc tgc atc cct	2956
Leu Pro Lys Asp Leu Pro Asp Trp Asp Trp Arg His Gly Cys Ile Pro	
840 845 850 855	
tgc cag aat atg gag tta ttt gct gtt ctc tgc ata gaa aca agc cac	3004
Cys Gln Asn Met Glu Leu Phe Ala Val Leu Cys Ile Glu Thr Ser His	
860 865 870	
tat gtt gct ttt gtg aag tat ggg aag gac gat tct gcc tgg ctc ttc	3052
Tyr Val Ala Phe Val Lys Tyr Gly Lys Asp Asp Ser Ala Trp Leu Phe	
875 880 885	
ttt gac agc atg gcc gat cgg gat ggt ggt cag aat ggc ttc aac att	3100
Phe Asp Ser Met Ala Asp Arg Asp Gly Gly Gln Asn Gly Phe Asn Ile	
890 895 900	
cct caa gtc acc cca tgc cca gaa gta gga gag tac ttg aag atg tct	3148
Pro Gln Val Thr Pro Cys Pro Glu Val Gly Glu Tyr Leu Lys Met Ser	
905 910 915	
ctg gaa gac ctg cat tcc ttg gac tcc agg aga atc caa ggc tgt gca	3196
Leu Glu Asp Leu His Ser Leu Asp Ser Arg Arg Ile Gln Gly Cys Ala	
920 925 930 935	
cga aga ctg ctt tgt gat gca tat atg tgc atg tac cag agt cca aca	3244
Arg Arg Leu Leu Cys Asp Ala Tyr Met Cys Met Tyr Gln Ser Pro Thr	
940 945 950	
atg agt ttg tac aaa taa ctgggggtcat cgaggaaaggc aaagaaactg	3292
Met Ser Leu Tyr Lys	
955	
aaggcagagt cctaacgttg catcttattc gagctggcag ttctgttcac gtccattgcc	3352
ggcaatggat gtctttgtgg tgatgatcct tcagaaaagg atgcctctgt ttaaaaacaa	3412
attgcttttg tgtccctgaa gtattttaata agaagcattt tgcactctag aaagtatgtt	3472
tgtgttggtt tttaagaag tctaaatgaa gttattaata cctgaagctt taagttaagt	3532
gcattgatca tatgatattt ttggaagcat acaattttaa ttgtggaagt ttaaagcctc	3592
ttttagtcca ttgagaatgt aaataaatgt gtcttcttta tggaccaagg atatgaaatc	3652

atTTTTcttt	tgtagctaac	ggttgccctg	aggaagaaat	aatttggttt	tattaagagt	3712
ctactctcaa	tccagttatt	agagatgtac	tgagtttgat	ttgttaatcc	tttctatata	3772
ctgctgatct	tgcattgtct	caatctgctc	agtttttctg	tgtttctgca	atagtgggtca	3832
gaaaaataact	taaattccct	taatgggtgt	gttttctatt	tgttctgggt	ttgagataaa	3892
tgagtgattc	tgtcccaaaa	tgtccatttt	tgaagtgatt	ttcctggagg	attaggggat	3952
ttagcagttg	aagctcttca	ttcatagtag	ttactgtcag	ctaacagggt	ttttaagggt	4012
tttaactatt	aatattttat	ggaatggggc	aaagtaaatt	gatgaaagaa	ttggagtgat	4072
aatagtcctt	tacaaacata	cagtcataa	gaaaatgaat	ttggcatata	gaattattac	4132
aatttcctgg	gagagatgga	tatttaaacc	tctattattt	tagacaagac	tgtctagaac	4192
ttaagtttga	tctgtcagcc	agtactccca	ttaaattcag	tgtagtttca	cttgatagaa	4252
tcagatatgt	tatcgaaatg	ttagcagcag	cttcacccct	cttctgatta	aagtaagtag	4312
aatgggatg	ttttgtttta	taacagccat	agtgtgtgtt	tagaccacag	cggtgtgtgt	4372
agaccaggac	catagatgat	acatgtcagt	gctgtggaat	gtgcattctc	tgagtgttgt	4432
tttgtggtat	cattgtcttt	cctgaatgac	tttctaactg	tgagaaaagg	cagaaaagtc	4492
atcatatgta	tatgtcatat	gactttataa	aatatttaat	gtgacaaaaa	gtggaaagaa	4552
tctttacaaa	ccctgcaatt	acttttttaa	aggcactttt	actctttggg	tttatcattc	4612
catttttgcta	atatttacta	gctttataaa	ttacagtaag	gtacaaaaac	tcatcttgta	4672
atattttcat	ttttgaagtg	aaaaagtaca	tatattttgc	acaaggtttt	atactgctaa	4732
gtgcttggtt	ggggtggtga	gatgatgatt	agatcagggg	tgaggctgag	agactctggg	4792
tttagggcta	gccctgcctc	catctccctt	gggtaaaatg	aagggtgtgg	ggtaaaagat	4852
gcataaggcc	ttttctagct	ctgacagcct	agaagtccaa	tcaccctgta	ataaatatgt	4912
gttgaatgaa	gaaatgggtg	aatgagcttg	tcaatgtgat	tttaaaaaat	tgactacctg	4972
gaggaatgat	taggaatcta	aatgaagcca	gccctcggtg	tctgcagggt	tctcatccat	5032
ggattcaacc	aactgcaa	ggaaaatacg	atTTTTTTT	aaaaaaggat	ggttacatcc	5092
gtattgaaca	tgtacagact	tttttcttgt	cattattctc	tgaacaatac	aagaactctt	5152
tatgtagcat	ttacatttat	taggtattat	aagtaatcta	gagattattt	aattaaaata	5212
tacaggagga	tgtgtgttta	tatgccagaa	attctgtacc	atTTTgtatc	agggaattga	5272
gcatcttcag	atgttggtat	ctgcagggat	cctggaacca	aaccctgca	gatactaagg	5332

gctgacgatac taggtaagac tggatttaac agttggaaa

5371

<210> 4

<211> 956

<212> PRT

<213> Homo sapiens

<400> 4

Met Ser Ser Gly Leu Trp Ser Gln Glu Lys Val Thr Ser Pro Tyr Trp
1 5 10 15

Glu Glu Arg Ile Phe Tyr Leu Leu Leu Gln Glu Cys Ser Val Thr Asp
20 25 30

Lys Gln Thr Gln Lys Leu Leu Lys Val Pro Lys Gly Ser Ile Gly Gln
35 40 45

Tyr Ile Gln Asp Arg Ser Val Gly His Ser Arg Ile Pro Ser Ala Lys
50 55 60

Gly Lys Lys Asn Gln Ile Gly Leu Lys Ile Leu Glu Gln Pro His Ala
65 70 75 80

Val Leu Phe Val Asp Glu Lys Asp Val Val Glu Ile Asn Glu Lys Phe
85 90 95

Thr Glu Leu Leu Leu Ala Ile Thr Asn Cys Glu Glu Arg Phe Ser Leu
100 105 110

Phe Lys Asn Arg Asn Arg Leu Ser Lys Gly Leu Gln Ile Asp Val Gly
115 120 125

Cys Pro Val Lys Val Gln Leu Arg Ser Gly Glu Glu Lys Phe Pro Gly
130 135 140

Val Val Arg Phe Arg Gly Pro Leu Leu Ala Glu Arg Thr Val Ser Gly
145 150 155 160

Ile Phe Phe Gly Val Glu Leu Leu Glu Glu Gly Arg Gly Gln Gly Phe
165 170 175

Thr Asp Gly Val Tyr Gln Gly Lys Gln Leu Phe Gln Cys Asp Glu Asp
 180 185 190

Cys Gly Val Phe Val Ala Leu Asp Lys Leu Glu Leu Ile Glu Asp Asp
 195 200 205

Asp Thr Ala Leu Glu Ser Asp Tyr Ala Gly Pro Gly Asp Thr Met Gln
 210 215 220

Val Glu Leu Pro Pro Leu Glu Ile Asn Ser Arg Val Ser Leu Lys Val
 225 230 235 240

Gly Glu Thr Ile Glu Ser Gly Thr Val Ile Phe Cys Asp Val Leu Pro
 245 250 255

Gly Lys Glu Ser Leu Gly Tyr Phe Val Gly Val Asp Met Asp Asn Pro
 260 265 270

Ile Gly Asn Trp Asp Gly Arg Phe Asp Gly Val Gln Leu Cys Ser Phe
 275 280 285

Ala Cys Val Glu Ser Thr Ile Leu Leu His Ile Asn Asp Ile Ile Pro
 290 295 300

Ala Leu Ser Glu Ser Val Thr Gln Glu Arg Arg Pro Pro Lys Leu Ala
 305 310 315 320

Phe Met Ser Arg Gly Val Gly Asp Lys Gly Ser Ser Ser His Asn Lys
 325 330 335

Pro Lys Ala Thr Gly Ser Thr Ser Asp Pro Gly Asn Arg Asn Arg Ser
 340 345 350

Glu Leu Phe Tyr Thr Leu Asn Gly Ser Ser Val Asp Ser Gln Pro Gln
 355 360 365

Ser Lys Ser Lys Asn Thr Trp Tyr Ile Asp Glu Val Ala Glu Asp Pro
 370 375 380

Ala Lys Ser Leu Thr Glu Ile Ser Thr Asp Phe Asp Arg Ser Ser Pro
 385 390 395 400

Pro Leu Gln Pro Pro Pro Val Asn Ser Leu Thr Thr Glu Asn Arg Phe
 405 410 415

His Ser Leu Pro Phe Ser Leu Thr Lys Met Pro Asn Thr Asn Gly Ser
 420 425 430

Ile Gly His Ser Pro Leu Ser Leu Ser Ala Gln Ser Val Met Glu Glu
 435 440 445

Leu Asn Thr Ala Pro Val Gln Glu Ser Pro Pro Leu Ala Met Pro Pro
 450 455 460

Gly Asn Ser His Gly Leu Glu Val Gly Ser Leu Ala Glu Val Lys Glu
 465 470 475 480

Asn Pro Pro Phe Tyr Gly Val Ile Arg Trp Ile Gly Gln Pro Pro Gly
 485 490 495

Leu Asn Glu Val Leu Ala Gly Leu Glu Leu Glu Asp Glu Cys Ala Gly
 500 505 510

Cys Thr Asp Gly Thr Phe Arg Gly Thr Arg Tyr Phe Thr Cys Ala Leu
 515 520 525

Lys Lys Ala Leu Phe Val Lys Leu Lys Ser Cys Arg Pro Asp Ser Arg
 530 535 540

Phe Ala Ser Leu Gln Pro Val Ser Asn Gln Ile Glu Arg Cys Asn Ser
 545 550 555 560

Leu Ala Phe Gly Gly Tyr Leu Ser Glu Val Val Glu Glu Asn Thr Pro
 565 570 575

Pro Lys Met Glu Lys Glu Gly Leu Glu Ile Met Ile Gly Lys Lys Lys
 580 585 590

Gly Ile Gln Gly His Tyr Asn Ser Cys Tyr Leu Asp Ser Thr Leu Phe
 595 600 605

Cys Leu Phe Ala Phe Ser Ser Val Leu Asp Thr Val Leu Leu Arg Pro
 610 615 620

Lys Glu Lys Asn Asp Val Glu Tyr Tyr Ser Glu Thr Gln Glu Leu Leu
625 630 635 640

Arg Thr Glu Ile Val Asn Pro Leu Arg Ile Tyr Gly Tyr Val Cys Ala
645 650 655

Thr Lys Ile Met Lys Leu Arg Lys Ile Leu Glu Lys Val Glu Ala Ala
660 665 670

Ser Gly Phe Thr Ser Glu Glu Lys Asp Pro Glu Glu Phe Leu Asn Ile
675 680 685

Leu Phe His His Ile Leu Arg Val Glu Pro Leu Leu Lys Ile Arg Ser
690 695 700

Ala Gly Gln Lys Val Gln Asp Cys Tyr Phe Tyr Gln Ile Phe Met Glu
705 710 715 720

Lys Asn Glu Lys Val Gly Val Pro Thr Ile Gln Gln Leu Leu Glu Trp
725 730 735

Ser Phe Ile Asn Ser Asn Leu Lys Phe Ala Glu Ala Pro Ser Cys Leu
740 745 750

Ile Ile Gln Met Pro Arg Phe Gly Lys Asp Phe Lys Leu Phe Lys Lys
755 760 765

Ile Phe Pro Ser Leu Glu Leu Asn Ile Thr Asp Leu Leu Glu Asp Thr
770 775 780

Pro Arg Gln Cys Arg Ile Cys Gly Gly Leu Ala Met Tyr Glu Cys Arg
785 790 795 800

Glu Cys Tyr Asp Asp Pro Asp Ile Ser Ala Gly Lys Ile Lys Gln Phe
805 810 815

Cys Lys Thr Cys Asn Thr Gln Val His Leu His Pro Lys Arg Leu Asn
820 825 830

His Lys Tyr Asn Pro Val Ser Leu Pro Lys Asp Leu Pro Asp Trp Asp
835 840 845

Trp Arg His Gly Cys Ile Pro Cys Gln Asn Met Glu Leu Phe Ala Val
850 855 860

Leu Cys Ile Glu Thr Ser His Tyr Val Ala Phe Val Lys Tyr Gly Lys
865 870 875 880

Asp Asp Ser Ala Trp Leu Phe Phe Asp Ser Met Ala Asp Arg Asp Gly
885 890 895

Gly Gln Asn Gly Phe Asn Ile Pro Gln Val Thr Pro Cys Pro Glu Val
900 905 910

Gly Glu Tyr Leu Lys Met Ser Leu Glu Asp Leu His Ser Leu Asp Ser
915 920 925

Arg Arg Ile Gln Gly Cys Ala Arg Arg Leu Leu Cys Asp Ala Tyr Met
930 935 940

Cys Met Tyr Gln Ser Pro Thr Met Ser Leu Tyr Lys
945 950 955

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092761 A3

(51) International Patent Classification⁷: **A61K 39/29**

(21) International Application Number: PCT/US02/14570

(22) International Filing Date: 7 May 2002 (07.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/851,673 8 May 2001 (08.05.2001) US

(71) Applicant (for all designated States except US): **IMMUNEX CORPORATION** [US/US]; Law Department, 51 University Street, Seattle, WA 98101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DERRY, Jonathan, M.J.** [GB/US]; 3998 El Cimo Lane, Bainbridge Island, WA 98110 (US). **FANSLOW, William, C., III** [US/US]; 404 S.W. 197th Street, Normandy Park, WA 98166 (US). **DOUGALL, William, Conrad** [US/US]; 7523 33rd Avenue Northwest, Seattle, WA 98117 (US).

(74) Agent: **PERKINS, Patricia, Anne**; IMMUNEX CORPORATION, 51 University Street, Seattle, WA 98101 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
3 April 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SCREENING ASSAYS FOR AGONISTS OR ANTAGONISTS OF CD40 SIGNALING

(57) Abstract: The present invention provides methods for identifying a molecule that antagonizes or agonizes CD40 activity by screening for molecules that modulate the binding of NEMO and CYLD. Also provided are assays useful in screening for the binding of NEMO and CYLD and databases and methods useful for analyzing the resultant information.

WO 02/092761 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/14570

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/29

US CL : 435/7.1; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Medline, EMBASE, US Patents, Derwent: Search Terms: NEMO, IKKgamma, signal?, bind?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MAY, M. J. et al. Selective inhibition of NF-kB Activation by a peptide that blocks the interaction of NEMO with the Ikb Kinase complex. Science. 01 September 2000, Vol. 289, pages 1550-1554, see entire document.	1-5
Y	HARHAJ, E.W. et al. IKKgamma serves as a docking subunit of the Ikb Kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus tax protein. The Journal of Biological Chemistry. 13 August 1999, Vol. 274, No. 33, pages 22911-22914, see entire document.	1-5
Y	JIN, D-Y. et al. Role of Adapter Function in oncoprotein-mediated activation of NF-kB. The Journal of Biological Chemistry. 18 June 1999, Vol. 274, no. 25, pages 17402-17406, see entire document.	1-5
X, P	TARASSISHIN, L. et al. SITES on FIP-3 (NEMO/ IKKgamma) essential for its phosphorylation and NF-kB Modulating activity. Biochem. Biophys. Res. Comm. September 2001, Vol. 285, pages 555-560, see entire document.	1-5

☒ Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

13 October 2002 (13.10.2002)

Date of mailing of the international search report

17 DEC 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks

Box PCT

Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Valerie Bell-Harris for
Mary K Zeman

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US02/14570

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	POYET, J-L. et al. Activation of the I κ B Kinases by RIP via IKKgamma/ NF κ B-mediated oligomerization. The Journal of Biological Chemistry. 01 December 2000, Vol. 275, No. 48, pages 37966-37977, see entire document.	1-5
X, P	US 6,365,366 B1 (CAO) 02 April 2002 (02.04.2002) see entire document.	1-5
Y, P	US 2002/0034780 A1 (MEYERS, R. et al.) 21 March 2002 (21.03.2002) see pages 28-30 and claim 22.	1-5
X, P	WO 01/83547 A2 (YALE UNIVERSITY) 08 November 2001 (08.11.2001) see entire document.	1-5
X, P	WO 01/83554 A2 (PRAECIS PHARMACEUTICALS INCORPORATED) 08 November 2001 (08.11.2001) see entire document.	1-5

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US02/14570

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-5, drawn to a method for identifying compounds.

Group II, claim(s) 6-12, drawn to database information.

Group III, claim(s) 13-22, drawn to a computer system.

Group IV, claim(s) 23-24, drawn to a method for increasing/decreasing activity.

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: : The special technical feature of Group I is the specific steps recited leading to the stated goal. This special technical feature is not shared by the other groups. The special technical feature of Group II is information. The special technical feature of Group III is the recited components of the computer system. The special technical feature of Group IV is the the specific steps recited leading to the stated goal. Note that the products of Groups II and III differ structurally and functionally and that the methods of Groups I and IV differ in their starting materials, method steps, and goals.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/14570

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-5

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

THIS PAGE BLANK (USPTO)